Advertisement

Pharmacy World & Science

, Volume 29, Issue 4, pp 350–352 | Cite as

Tuberous sclerosis successfully treated with levetiracetam monotherapy: 18 months of follow-up

  • Savvas S. PapacostasEmail author
  • Eleftherios S. Papathanasiou
  • Panayiota Myrianthopoulou
  • Goula Stylianidou
Report

Abstract

Case

We present the case of a boy with tuberous sclerosis who was referred for evaluation and treatment of his intractable epileptic seizures, having failed multiple anti-epileptic drug trials. He was subsequently treated with Levetiracetam that was gradually titrated to an effective dose, achieving full suppression of his seizures. Thereafter, his concomitant anti-epileptic drugs were gradually reduced and eventually discontinued. He remained on monotherapy with Levetiracetam, which continued to fully control his seizures. His EEG tracings before and after treatment are presented and compared, showing normalization of the latter.

Conclusion

Levetiracetam appears to be effective in treatment-resistant seizures which are symptomatic to tuberous sclerosis when used adjunctively as well as in monotherapy. This is the first report in the English literature regarding its use and efficacy in this condition.

Keywords

Levetiracetam Tuberous sclerosis Seizures 

References

  1. 1.
    Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006;355(13):1345–1356PubMedCrossRefGoogle Scholar
  2. 2.
    Connoly MB, Hendson G, Steinbok P. Tuberous sclerosis complex: a review of the management of epilepsy with emphasis on surgical aspects. Childs Nerv Syst 2006;22(8):896–908CrossRefGoogle Scholar
  3. 3.
    Niespodziany I, Klitgaard H, Margineanu D-G. Levetiracetam inhibits the high-voltage activated Ca2 +  current in pyramidal neurons of rat hippocampal slices. Neurosci Lett 2001;306:5–8PubMedCrossRefGoogle Scholar
  4. 4.
    Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated current. Br J Pharmacol 2000;136:659–672CrossRefGoogle Scholar
  5. 5.
    Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004;101(26):9861–6 Jun 29PubMedCrossRefGoogle Scholar
  6. 6.
    Collins JJ, Tudor C, Leonard JM, Chuck G, Franz DN. Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial. J Child Neurol. 2006;21(1):53–7 JanPubMedCrossRefGoogle Scholar
  7. 7.
    Labate A, Colosimo E, Gambardella A, et al. Levetiracetam in patients with generalized epilepsy and myoclonic seizures: an open label study. Seizure 2006;15(3):214–8PubMedCrossRefGoogle Scholar
  8. 8.
    Coppola G, Franzoni E, Verrotti A, Garone C, Sarajlija J, Felicia Operto F, Pascotto A. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial. Brain Dev 2006; Oct 19Google Scholar
  9. 9.
    Cloyd JC, Remmel RP. Antiepileptic drug pharmacokinetics and interactions: impact on treatment of epilepsy. Pharmacotherapy 2000;85:77–85Google Scholar
  10. 10.
    Ji-qun C, Ishihara K, Nagayama T, et al. Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs. Epilepsia 2005;46(9):1362–1370PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Savvas S. Papacostas
    • 1
    • 2
    Email author
  • Eleftherios S. Papathanasiou
    • 2
  • Panayiota Myrianthopoulou
    • 2
  • Goula Stylianidou
    • 3
  1. 1.Department of NeurologyThe Cyprus Institute of Neurology and GeneticsNicosiaCyprus
  2. 2.Department of NeurophysiologyThe Cyprus Institute of Neurology and GeneticsNicosiaCyprus
  3. 3.Department of PediatricsArch. Makarios III HospitalNicosiaCyprus

Personalised recommendations